Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$120000.0.

  • Insight Molecular Diagnostics' Cash from Financing Activities rose 5294.12% to -$120000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $39.2 million, marking a year-over-year increase of 30954.82%. This contributed to the annual value of $20.4 million for FY2024, which is 6764.32% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Cash from Financing Activities stood at -$120000.0 for Q3 2025, which was up 5294.12% from -$114000.0 recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Cash from Financing Activities peaked at $69.9 million during Q1 2021, and registered a low of -$528000.0 during Q3 2022.
  • Over the past 5 years, Insight Molecular Diagnostics' median Cash from Financing Activities value was -$29000.0 (recorded in 2023), while the average stood at $9.7 million.
  • Within the past 5 years, the most significant YoY rise in Insight Molecular Diagnostics' Cash from Financing Activities was 3622333.33% (2024), while the steepest drop was 75000.0% (2024).
  • Insight Molecular Diagnostics' Cash from Financing Activities (Quarter) stood at -$269000.0 in 2021, then skyrocketed by 62.83% to -$100000.0 in 2022, then soared by 70.0% to -$30000.0 in 2023, then skyrocketed by 36223.33% to $10.8 million in 2024, then tumbled by 101.11% to -$120000.0 in 2025.
  • Its Cash from Financing Activities stands at -$120000.0 for Q3 2025, versus -$114000.0 for Q2 2025 and $28.6 million for Q1 2025.